Filing Flows › Karyopharm Therapeutics (KPTI) › Stock forecast & fair value
Karyopharm Therapeutics (KPTI) stock forecast and price target
Karyopharm Therapeutics (KPTI) trades at $0.05. 4 analysts' median price target is $7.50 (137×), from $3.00 to $11.00.
Karyopharm Therapeutics' latest quarter
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for KPTI stock?
The median of 4 analysts' 12-month targets is $7.50, 137× from $0.05; the range is $3.00 to $11.00. The average rating is none.
Does Karyopharm Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is KPTI stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.